In the latest published clinical trial data, the oral anti-cancer drug developed by Revolution Medicines showed significant efficacy, successfully extending the survival of patients with advanced cancer.

Boosted by this favorable news, the company's stock price surged 33.5% in pre-market trading, marking the largest single-day increase in recent times. The phase III study targeting patients with advanced solid tumors showed that, compared to the current standard therapy, the group treated with Revolution Medicines' experimental drug achieved a statistically significant improvement in overall survival. This breakthrough brings new hope to patient groups facing limited treatment options, while also confirming the clinical value of the company’s targeted anti-cancer technology platform. Market analysts pointed out that this positive data not only strengthens the possibility of the drug being approved for market release but also highlights the company's leading position in the field of RAS pathway inhibitors. As further research and development progresses, this therapy is expected to become an important treatment option for specific cancer subtypes.